On May 31, 2016, the Company entered into a one year contract with Barcelona Boosting Business SL ("BBB") to coordinate a clinical trial of the Licensed Technology in Barcelona, Spain in a study for up to 25 patients (the "Study"). BBB will be compensated 20,000 EURO at the start of the contract and 18,500 EURO after the submission of the Study. During the term of the contract BBB will protect the Company's proprietary information, patents, patent applications, copyrights and other intellectual property rights. All inventions from the Study shall be the exclusive property of the Company.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM